Compare C3.ai Inc (AI) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Incyte Corporation — how do they compare? C3.ai Inc trades at $10.14 (market cap $1.65B), while Incyte Corporation trades at $120.67 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 14.9× C3.ai Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| AI | INCY | |
|---|---|---|
Market Cap | $1.65B | $24.54B |
Sector | Technology | Health |
52-Week High | $19.66 | $129.93 |
52-Week Low | $7.76 | $81.61 |
Enterprise Value | $1.08B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.25, down 1.44% on the day, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company maintains strong revenue growth, reaching $389 million in 2025, but continues to report significant losses with a -74.21% net margin. Recent positive developments include being named a Leader in AI Platforms by Forrester Research.
While technical indicators suggest short-term bullish momentum, fundamental challenges persist with consistent negative profitability. The stock faces execution risk in achieving profitability despite growing enterprise AI adoption. Analyst consensus remains cautious with only 21% buy ratings and a $10.20 price target slightly below current levels.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
